Show simple item record

dc.contributor.authorMielke, O
dc.contributor.authorBril, V
dc.contributor.authorCornblath, DR
dc.contributor.authorLawo, JP
dc.contributor.authorvan Geloven, N
dc.contributor.authorHartung, HP
dc.contributor.authorLewis, RA
dc.contributor.authorMerkies, ISJ
dc.contributor.authorSobue, G
dc.contributor.authorDurn, B
dc.contributor.authorShebl, A
dc.contributor.authorvan Schaik, IN
dc.contributor.authorSabet, A
dc.contributor.authorGeorge, K
dc.contributor.authoret al.
dc.date.accessioned2020-08-20T04:10:13Z
dc.date.available2020-08-20T04:10:13Z
dc.date.issued2019
dc.identifier.issn1085-9489
dc.identifier.doi10.1111/jns.12303
dc.identifier.urihttp://hdl.handle.net/10072/396595
dc.description.abstractIn patients with chronic inflammatory demyelinating polyneuropathy (CIDP), intravenous immunoglobulin (IVIG) is recommended to be periodically reduced to assess the need for ongoing therapy. However, little is known about the effectiveness of restabilization with IVIG in patients who worsen after IVIG withdrawal. In the Polyneuropathy And Treatment with Hizentra (PATH) study, the pre‐randomization period included sudden stopping of IVIG followed by 12 weeks of observation. Those deteriorating were then restabilized with IVIG. Of 245 subjects who stopped IVIG, 28 did not show signs of clinical deterioration within 12 weeks. Two hundred and seven received IVIG restabilization with an induction dose of 2 g/kg bodyweight (bw) IgPro10 (Privigen, CSL Behring, King of Prussia, Pennsylvania) and maintenance doses of 1 g/kg bw every 3 weeks for up to 13 weeks. Signs of clinical improvement were seen in almost all (n = 188; 91%) subjects. During IVIG restabilization, 35 subjects either did not show CIDP stability (n = 21, analyzed as n = 22 as an additional subject was randomized in error) or withdrew for other reasons (n = 14). Of the 22 subjects who did not achieve clinical stability, follow‐up information in 16 subjects after an additional 4 weeks was obtained. Nine subjects were reported to have improved, leaving a maximum of 27 subjects (13%) who either showed no signs of clinical improvement during the restabilization phase and 4 weeks post‐study or withdrew for other reasons. In conclusion, sudden IVIG withdrawal was effective in detecting ongoing immunoglobulin G dependency with a small risk for subjects not returning to their baseline 17 weeks after withdrawal.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofpagefrom72
dc.relation.ispartofpageto79
dc.relation.ispartofissue1
dc.relation.ispartofjournalJournal of the Peripheral Nervous System
dc.relation.ispartofvolume24
dc.subject.fieldofresearchNeurosciences
dc.subject.fieldofresearchcode3209
dc.subject.keywordsPrivigen
dc.subject.keywordschronic inflammatory demyelinating polyneuropathy (CIDP)
dc.subject.keywordsinflammatory neuropathy cause and treatment (INCAT)
dc.subject.keywordsintravenous immunoglobulin (IVIG)
dc.subject.keywordspolyneuropathy and treatment with Hizentra (PATH)
dc.titleRestabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationMielke, et al., Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study, Journal of the Peripheral Nervous System, 2019, 24 (1), pp. 72-79
dcterms.dateAccepted2019-01-12
dcterms.licensehttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.date.updated2020-08-20T04:07:21Z
dc.description.versionVersion of Record (VoR)
gro.rights.copyright© 2019 CSL Behring. Journal of the Peripheral Nervous System published by Wiley Periodicals, Inc. on behalf of Peripheral Nerve Society. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
gro.hasfulltextFull Text
gro.griffith.authorSabet, Arman


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record